Skip to main content
Top
Published in: Clinical Research in Cardiology 12/2014

01-12-2014 | Original Paper

A high ratio of ADP–TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone

Authors: Christoph B. Olivier, Katharina Schnabel, Christoph Brandt, Patrick Weik, Manfred Olschewski, Qian Zhou, Christoph Bode, Philipp Diehl, Martin Moser

Published in: Clinical Research in Cardiology | Issue 12/2014

Login to get access

Abstract

Objective

This study aimed to evaluate whether a high relative ADP induced aggregation (r-ADP-agg) is associated with an increased mortality in patients after coronary stent implantation.

Background

Several trials were not able to improve clinical outcome by adapting platelet inhibition in patients after coronary stent implantation and high platelet reactivity (HPR). Platelet monitoring is complex and conventional definition of adenosindiphosphate (ADP) induced aggregation alone might not transfer the whole picture of adequate platelet inhibition in vivo.

Methods

In a prospective single-centre observational trial multiple electrode aggregometry was performed in whole blood of patients after stent implantation. r-ADP-agg was defined as the ADP–thrombin receptor activating peptide ratio to reflect an individual degree of P2Y12 dependent platelet inhibition with a cut-off value for HPR of ≥50 %. The primary end point was mortality.

Results

Follow-up was completed in 176 of 184 patients (96 %) with a mean follow-up time of 3.7 years. 35 (20 %) patients revealed an r-ADP-agg ≥50 %. An r-ADP-agg ≥50 % was associated with an increased mortality [unadjusted hazard ratio (HR) 7.006 (2.561–19.17); p = 0.0001]. In a multivariable Cox regression analysis mortality was independently associated with an r-ADP-agg ≥50 % [HR 3.324 (1.542–7.165); p = 0.0022], ACS-setting [HR 3.249 (1.322–7.989); p = 0.0102] and severely reduced LV function [HR 5.463 (2.098–14.26); p = 0.0005].

Conclusion

An r-ADP-agg ≥50 % is associated with an increased mortality in patients after coronary stent implantation. Furthermore, r-ADP-agg might represent a better tool to predict clinical outcome than the conventional ADP induced platelet aggregation alone.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lopez AD, Mathers CD, Ezzati M et al (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747–1757PubMedCrossRef Lopez AD, Mathers CD, Ezzati M et al (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747–1757PubMedCrossRef
2.
go back to reference Sofi F, Marcucci R, Gori AM et al (2010) Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 103:841–848PubMedCrossRef Sofi F, Marcucci R, Gori AM et al (2010) Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 103:841–848PubMedCrossRef
3.
go back to reference Trip MD, Cats VM, van Capelle FJ et al (1990) Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322:1549–1554PubMedCrossRef Trip MD, Cats VM, van Capelle FJ et al (1990) Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322:1549–1554PubMedCrossRef
4.
go back to reference Muller I, Besta F, Schulz C et al (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89:783–787PubMed Muller I, Besta F, Schulz C et al (2003) Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89:783–787PubMed
5.
go back to reference Zeymer U, Arntz HR, Mark B et al (2012) Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 101:305–312PubMedCrossRef Zeymer U, Arntz HR, Mark B et al (2012) Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 101:305–312PubMedCrossRef
6.
go back to reference Diehl P, Olivier C, Halscheid C et al (2010) Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol 105:379–387PubMedCrossRef Diehl P, Olivier C, Halscheid C et al (2010) Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol 105:379–387PubMedCrossRef
7.
go back to reference Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614–623PubMedCrossRef Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614–623PubMedCrossRef
8.
go back to reference Collet JP, Cuisset T, Range G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109PubMedCrossRef Collet JP, Cuisset T, Range G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109PubMedCrossRef
9.
go back to reference Gurbel PA, Erlinge D, Ohman EM et al (2012) Platelet function during extended prasugrel and clopidogrel Therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308(17):1785–1794. doi:10.1001/jama.2012.17312 Gurbel PA, Erlinge D, Ohman EM et al (2012) Platelet function during extended prasugrel and clopidogrel Therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308(17):1785–1794. doi:10.​1001/​jama.​2012.​17312
10.
go back to reference Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105PubMedCrossRef Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105PubMedCrossRef
11.
go back to reference Trenk D, Stone GW, Gawaz M et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 59:2159–2164PubMedCrossRef Trenk D, Stone GW, Gawaz M et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 59:2159–2164PubMedCrossRef
12.
go back to reference Voisin S, Bongard V, Tidjane MA et al (2011) Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels. Thromb Haemost 106:227–229PubMedCrossRef Voisin S, Bongard V, Tidjane MA et al (2011) Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels. Thromb Haemost 106:227–229PubMedCrossRef
13.
go back to reference Gremmel T, Calatzis A, Steiner S et al (2010) Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel? Platelets 21:515–521PubMedCrossRef Gremmel T, Calatzis A, Steiner S et al (2010) Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel? Platelets 21:515–521PubMedCrossRef
14.
go back to reference Olivier C, Diehl P, Bode C et al (2013) Thrombin receptor antagonism in antiplatelet therapy. Cardiol Therapy 2:57–68CrossRef Olivier C, Diehl P, Bode C et al (2013) Thrombin receptor antagonism in antiplatelet therapy. Cardiol Therapy 2:57–68CrossRef
15.
go back to reference Olivier CB, Diehl P, Schnabel K et al (2013) Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thromb Haemost 111:266–272PubMedCrossRef Olivier CB, Diehl P, Schnabel K et al (2013) Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thromb Haemost 111:266–272PubMedCrossRef
16.
go back to reference Diehl P, Halscheid C, Olivier C et al (2011) Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol 100:765–771PubMedCrossRef Diehl P, Halscheid C, Olivier C et al (2011) Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol 100:765–771PubMedCrossRef
17.
go back to reference Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef
18.
go back to reference Chesebro JH, Knatterud G, Roberts R et al (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142–154PubMedCrossRef Chesebro JH, Knatterud G, Roberts R et al (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142–154PubMedCrossRef
19.
go back to reference Peduzzi P, Concato J, Feinstein AR et al (1995) Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48:1503–1510PubMedCrossRef Peduzzi P, Concato J, Feinstein AR et al (1995) Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48:1503–1510PubMedCrossRef
20.
go back to reference Kwok CS, Jeevanantham V, Dawn B et al (2013) No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol 167:965–974PubMedCrossRef Kwok CS, Jeevanantham V, Dawn B et al (2013) No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol 167:965–974PubMedCrossRef
21.
go back to reference Geisler T, Langer H, Wydymus M et al (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27:2420–2425PubMedCrossRef Geisler T, Langer H, Wydymus M et al (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27:2420–2425PubMedCrossRef
22.
go back to reference Badr Eslam R, Lang IM, Koppensteiner R et al (2012) Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. Int J Cardiol 168(1):403–406. doi:10.1016/j.ijcard.2012.09.103 Badr Eslam R, Lang IM, Koppensteiner R et al (2012) Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. Int J Cardiol 168(1):403–406. doi:10.​1016/​j.​ijcard.​2012.​09.​103
23.
go back to reference Steg PG, Fox KA, Eagle KA et al (2009) Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the global registry of acute coronary events. Eur Heart J 30:321–329PubMedCrossRef Steg PG, Fox KA, Eagle KA et al (2009) Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the global registry of acute coronary events. Eur Heart J 30:321–329PubMedCrossRef
24.
go back to reference Aradi D, Tornyos A, Pinter T et al (2014) Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63:1061–1070PubMedCrossRef Aradi D, Tornyos A, Pinter T et al (2014) Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63:1061–1070PubMedCrossRef
25.
go back to reference Seivani Y, Abdel-Wahab M, Geist V et al (2013) Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol 102:799–806PubMedCrossRef Seivani Y, Abdel-Wahab M, Geist V et al (2013) Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol 102:799–806PubMedCrossRef
26.
go back to reference Liosis S, Bauer T, Schiele R et al (2013) Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study. Clin Res Cardiol 102:671–677PubMedCrossRef Liosis S, Bauer T, Schiele R et al (2013) Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study. Clin Res Cardiol 102:671–677PubMedCrossRef
27.
go back to reference Theidel U, Asseburg C, Giannitsis E et al (2013) Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol 102:447–458PubMedCrossRef Theidel U, Asseburg C, Giannitsis E et al (2013) Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol 102:447–458PubMedCrossRef
28.
go back to reference Stark R, Kirchberger I, Hunger M et al (2014) Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines. Clin Res Cardiol 103:237–245PubMedCrossRef Stark R, Kirchberger I, Hunger M et al (2014) Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines. Clin Res Cardiol 103:237–245PubMedCrossRef
29.
go back to reference Zusman O, Amit G, Gilutz H et al (2012) The significance of new onset atrial fibrillation complicating acute myocardial infarction. Clin Res Cardiol 101:17–22PubMedCrossRef Zusman O, Amit G, Gilutz H et al (2012) The significance of new onset atrial fibrillation complicating acute myocardial infarction. Clin Res Cardiol 101:17–22PubMedCrossRef
30.
go back to reference Gremmel T, Steiner S, Seidinger D et al (2009) Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 101:333–339PubMed Gremmel T, Steiner S, Seidinger D et al (2009) Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 101:333–339PubMed
Metadata
Title
A high ratio of ADP–TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone
Authors
Christoph B. Olivier
Katharina Schnabel
Christoph Brandt
Patrick Weik
Manfred Olschewski
Qian Zhou
Christoph Bode
Philipp Diehl
Martin Moser
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 12/2014
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-014-0737-8

Other articles of this Issue 12/2014

Clinical Research in Cardiology 12/2014 Go to the issue